Citations (47)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (15)
Longfei Lin & Hui Li. (2021) Analysis of Clinical Trials of New Drugs for Liver Diseases in China. Drug Design, Development and Therapy 15, pages 3181-3191.
Read now
Read now
Saravanan Manjula, Magudeeswaran Sivanandam & Poomani Kumaradhas. (2019) Probing the “fingers” domain binding pocket of Hepatitis C virus NS5B RdRp and D559G resistance mutation via molecular docking, molecular dynamics simulation and binding free energy calculations. Journal of Biomolecular Structure and Dynamics 37:9, pages 2440-2456.
Read now
Read now
Guglielmo Borgia, Alberto Enrico Maraolo, Salvatore Nappa, Ivan Gentile & Antonio Riccardo Buonomo. (2018) NS5B polymerase inhibitors in phase II clinical trials for HCV infection. Expert Opinion on Investigational Drugs 27:3, pages 243-250.
Read now
Read now
Isabella Esposito, Julieta Trinks & Vicente Soriano. (2016) Hepatitis C virus resistance to the new direct-acting antivirals. Expert Opinion on Drug Metabolism & Toxicology 12:10, pages 1197-1209.
Read now
Read now
Robert Cox & Richard K. Plemper. (2016) Structure-guided design of small-molecule therapeutics against RSV disease. Expert Opinion on Drug Discovery 11:6, pages 543-556.
Read now
Read now
Parvez S. Mantry & Lakshmikant Pathak. (2016) Dasabuvir (ABT333) for the treatment of chronic HCV genotype I: a new face of cure, an expert review. Expert Review of Anti-infective Therapy 14:2, pages 157-165.
Read now
Read now
Vincent Soriano, Pablo Labarga, Carmen de Mendoza, José V Fernández-Montero, Isabella Esposito, Laura Benítez-Gutiérrez, José M Peña & Pablo Barreiro. (2016) New hepatitis C therapies for special patient populations. Expert Opinion on Pharmacotherapy 17:2, pages 217-229.
Read now
Read now
Sujit V Janardhan & Nancy S Reau. (2015) Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?. Hepatic Medicine: Evidence and Research 7, pages 11-20.
Read now
Read now
Ivan Gentile, Alberto Enrico Maraolo, Antonio Riccardo Buonomo, Emanuela Zappulo & Guglielmo Borgia. (2015) The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C. Expert Opinion on Drug Discovery 10:12, pages 1363-1377.
Read now
Read now
Vincent Soriano, Pablo Labarga, Pablo Barreiro, José V Fernandez-Montero, Carmen de Mendoza, Isabella Esposito, Laura Benítez-Gutiérrez & José M Peña. (2015) Drug interactions with new hepatitis C oral drugs. Expert Opinion on Drug Metabolism & Toxicology 11:3, pages 333-341.
Read now
Read now
Amanda Fifi, Andrea Barreto & Aymin Delgado-Borrego. (2014) Optimal management of pediatric hepatitis C infection: a review. Pediatric Health, Medicine and Therapeutics 5, pages 173-184.
Read now
Read now
Ivan Gentile, Antonio Riccardo Buonomo, Emanuela Zappulo, Nicola Coppola & Guglielmo Borgia. (2014) GS-9669: a novel non-nucleoside inhibitor of viral polymerase for the treatment of hepatitis C virus infection. Expert Review of Anti-infective Therapy 12:10, pages 1179-1186.
Read now
Read now
Ivan Gentile, Nicola Coppola, Antonio Riccardo Buonomo, Emanuela Zappulo & Guglielmo Borgia. (2014) Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus. Expert Opinion on Investigational Drugs 23:9, pages 1211-1223.
Read now
Read now
Emily J Cartwright & Lesley Miller. (2013) Novel drugs in the management of difficult-to-treat hepatitis C genotypes. Hepatic Medicine: Evidence and Research 5, pages 53-61.
Read now
Read now
David M You & Paul J Pockros. (2013)
Simeprevir for the treatment of chronic hepatitis C. Expert Opinion on Pharmacotherapy 14:18, pages 2581-2589.
Read now
Read now
Articles from other publishers (32)
Saleh A. Alqahtani & Mark S. Sulkowski. (2023) Chronic Hepatitis C. Medical Clinics of North America 107:3, pages 423-433.
Crossref
Crossref
Filippo Gabrielli, Francesco Alberti, Cristina Russo, Carmela Cursaro, Hajrie Seferi, Marzia Margotti & Pietro Andreone. (2023) Treatment Options for Hepatitis A and E: A Non-Systematic Review. Viruses 15:5, pages 1080.
Crossref
Crossref
Longhu Zhou, Hongwang Zhang, Chengwei Li, Coralie De Schutter, Ozkan Sari, Seema Mengshetti, Shaoman Zhou, Mahesh Kasthuri, Steven J. Coats, Raymond F. Schinazi & Franck Amblard. (2021) Diastereoselective Synthesis of 2′-Dihalopyrimidine Ribonucleoside Inhibitors of Hepatitis C Virus Replication. ACS Omega 7:1, pages 1452-1461.
Crossref
Crossref
Hui-Chun Li, Chee-Hing Yang & Shih-Yen Lo. (2021) Hepatitis C Viral Replication Complex. Viruses 13:3, pages 520.
Crossref
Crossref
Nehal Ibrahim & Ashaimaa Y. Moussa. (2021) A comparative volatilomic characterization of Florence fennel from different locations: antiviral prospects. Food & Function 12:4, pages 1498-1515.
Crossref
Crossref
Di Han, Huiqun Wang, Baerlike Wujieti, Beibei Zhang, Wei Cui & Bo-Zhen Chen. (2021) Insight into the drug resistance mechanisms of GS-9669 caused by mutations of HCV NS5B polymerase via molecular simulation. Computational and Structural Biotechnology Journal 19, pages 2761-2774.
Crossref
Crossref
José A. Gálvez, Rafael Clavería-Gimeno, Juan J. Galano-Frutos, Javier Sancho, Adrian Velázquez-Campoy, Olga Abian & María D. Díaz-de-Villegas. (2019) Stereoselective synthesis and biological evaluation as inhibitors of hepatitis C virus RNA polymerase of GSK3082 analogues with structural diversity at the 5-position. European Journal of Medicinal Chemistry 171, pages 401-419.
Crossref
Crossref
Seema Mengshetti, Longhu Zhou, Ozkan Sari, Coralie De Schutter, Hongwang Zhang, Jong Hyun Cho, Sijia Tao, Leda C. Bassit, Kiran Verma, Robert A. Domaoal, Maryam Ehteshami, Yong Jiang, Reuben Ovadia, Mahesh Kasthuri, Olivia Ollinger Russell, Tamara McBrayer, Tony Whitaker, Judy Pattassery, Maria Luz Pascual, Lothar Uher, Biing Y. Lin, Sam Lee, Franck Amblard, Steven J. Coats & Raymond F. Schinazi. (2019) Discovery of a Series of 2′-α-Fluoro,2′-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus. Journal of Medicinal Chemistry 62:4, pages 1859-1874.
Crossref
Crossref
Darrick K. Li & Raymond T. Chung. 2019. Hepatitis C Virus Protocols. Hepatitis C Virus Protocols
3
32
.
Fatma Abdallah, Gehad Mohamed, Mohsen Ibrahim & Mokhtar El Tarabily. (2018) Effectiveness of Sofosbuvir, Ribavirin and PEG-IFNα-2a in the Treatment of Naïve Egyptian Patients With Chronic Hepatitis C Virus Genotype 4. The American Journal of the Medical Sciences 355:5, pages 456-466.
Crossref
Crossref
Ruben Brandão, Rute Marcelino, Fátima Gonçalves, Isabel Diogo, Ana Carvalho, Joaquim Cabanas, Inês Costa, Pedro Brogueira, Fernando Ventura, Ana Miranda, Kamal Mansinho & Perpétua Gomes. (2018) Characterization of NS5A and NS5B Resistance-Associated Substitutions from Genotype 1 Hepatitis C Virus Infected Patients in a Portuguese Cohort. Viruses 10:5, pages 223.
Crossref
Crossref
Mansuri Reema, Patel Dhara, Patel Khushboo & Meshram Dhananjay. (2018) In depth investigation of quantitative analytical and bioanalytical techniques of hepatitic drug sofosbuvir in different matrices: a review. Journal of Analytical & Pharmaceutical Research 7:2.
Crossref
Crossref
J. Sun, X. Liang, R. Fan & J. Hou. (2018) Editorial: sofosbuvir plus daclatasvir for the treatment of hepatitis C-can one size fit all?. Alimentary Pharmacology & Therapeutics 47:6, pages 853-854.
Crossref
Crossref
Hussien Ahmed, Abdelrahman I. Abushouk, Attia Attia, Mohamed Gadelkarim, Mohamed Gabr, Ahmed Negida & Mohamed M. Abdel-Daim. (2018) Safety and efficacy of sofosbuvir plus velpatasvir with or without ribavirin for chronic hepatitis C virus infection: A systematic review and meta-analysis. Journal of Infection and Public Health 11:2, pages 156-164.
Crossref
Crossref
Gary B. Evans, Peter C. Tyler & Vern L. Schramm. (2017) Immucillins in Infectious Diseases. ACS Infectious Diseases 4:2, pages 107-117.
Crossref
Crossref
John T. Randolph, A. Chris Krueger, Pamela L. Donner, John K. Pratt, Dachun Liu, Christopher E. Motter, Todd W. Rockway, Michael D. Tufano, Rolf Wagner, Hock B. Lim, Jill M. Beyer, Rubina Mondal, Neeta S. Panchal, Lynn Colletti, Yaya Liu, Gennadiy Koev, Warren M. Kati, Lisa E. Hernandez, David W. A. Beno, Kenton L. Longenecker, Kent D. Stewart, Emily O. Dumas, Akhteruzzaman Molla & Clarence J. Maring. (2018)
Synthesis and Biological Characterization of Aryl Uracil Inhibitors of Hepatitis C Virus NS5B Polymerase: Discovery of ABT-072, a
trans
-Stilbene Analog with Good Oral Bioavailability
. Journal of Medicinal Chemistry 61:3, pages 1153-1163.
Crossref
Crossref
Sanaa M. Kamal. 2018. Hepatitis C in Developing Countries. Hepatitis C in Developing Countries
209
246
.
Lize Cuypers, Francesca Ceccherini-Silberstein, Kristel Van Laethem, Guangdi Li, Anne-Mieke Vandamme & Jürgen Kurt Rockstroh. (2016) Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time. Reviews in Medical Virology 26:6, pages 408-434.
Crossref
Crossref
Dimas Alexandre Kliemann, Cristiane Valle Tovo, Ana Beatriz Gorini da Veiga, Angelo Alves de Mattos & Charles Wood. (2016) Polymorphisms and resistance mutations of hepatitis C virus on sequences in the European hepatitis C virus database. World Journal of Gastroenterology 22:40, pages 8910.
Crossref
Crossref
Shinya Maekawa & Nobuyuki Enomoto. 2016. Hepatitis C Virus II. Hepatitis C Virus II
243
256
.
Hye Jin Yang, Ju Yeon Ryoo & Bong Kyu Yoo. (2015) Meta-analysis of the efficacy and safety of sofosbuvir for the treatment of hepatitis C virus infection. International Journal of Clinical Pharmacy 37:5, pages 698-708.
Crossref
Crossref
Gwenaëlle Sizun, Claire Pierra, Jérôme Peyronnet, Eric Badaroux, Céline Rabeson, Samira Benzaria-Prad, Dominique Surleraux, Anna Giulia Loi, Chiara Musiu, Michel Liuzzi, Maria Seifer, David Standring, Jean-Pierre Sommadossi & Gilles Gosselin. (2015)
Design, synthesis and antiviral evaluation of 2′-
C
-methyl branched guanosine pronucleotides: the discovery of IDX184, a potent liver-targeted HCV polymerase inhibitor
. Future Medicinal Chemistry 7:13, pages 1675-1700.
Crossref
Crossref
Robert Cox & Richard K. Plemper. (2015) The paramyxovirus polymerase complex as a target for next-generation anti-paramyxovirus therapeutics. Frontiers in Microbiology 6.
Crossref
Crossref
C. Nelson Hayes & Kazuaki Chayama. (2015) Emerging treatments for chronic hepatitis C. Journal of the Formosan Medical Association 114:3, pages 204-215.
Crossref
Crossref
Pablo Labarga, Jose V Fernández-Montero, Mariola López, Pablo Barreiro, Carmen de Mendoza, Rocío Sierra-Enguita, Ana Treviño & Vincent Soriano. (2013) Progression to Advanced Liver Fibrosis in HIV–HCV-Coinfected Patients and Prioritization of New Hepatitis C Therapies. Antiviral Therapy 19:8, pages 799-803.
Crossref
Crossref
Nadia Marascio, Carlo Torti, Maria Carla Liberto & Alfredo Focà. (2014) Updateon different aspects of HCV variability: focus on NS5B polymerase. BMC Infectious Diseases 14:S5.
Crossref
Crossref
Eva Poveda, David L. Wyles, Álvaro Mena, José D. Pedreira, Ángeles Castro-Iglesias & Edward Cachay. (2014) Update on hepatitis C virus resistance to direct-acting antiviral agents. Antiviral Research 108, pages 181-191.
Crossref
Crossref
Pablo Barreiro, Jose Vicente Fernandez-Montero, Carmen de Mendoza, Pablo Labarga & Vincent Soriano. (2014) Towards hepatitis C eradication from the HIV-infected population. Antiviral Research 105, pages 1-7.
Crossref
Crossref
Weiwei Xue, Pingzu Jiao, Huanxiang Liu & Xiaojun Yao. (2014) Molecular modeling and residue interaction network studies on the mechanism of binding and resistance of the HCV NS5B polymerase mutants to VX-222 and ANA598. Antiviral Research 104, pages 40-51.
Crossref
Crossref
Daniele Serranti, Giuseppe Indolfi & Massimo Resti. (2014) New treatments for chronic hepatitis C: An overview for paediatricians. World Journal of Gastroenterology 20:43, pages 15965.
Crossref
Crossref
Anand C. Patel. (2013) Clinical Relevance of Target Identity and Biology: Implications for Drug Discovery and Development. SLAS Discovery 18:10, pages 1164-1185.
Crossref
Crossref
José Vicente Fernández-Montero, Eugenia Vispo, Pablo Barreiro, Carmen Mendoza, Pablo Labarga & Vincent Soriano. (2013) Treatment of Hepatitis C in HIV Patients in the New Era of Direct-Acting Antivirals. Current Hepatitis Reports 12:4, pages 269-275.
Crossref
Crossref